Compare DUOT & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DUOT | CABA |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.5M | 210.8M |
| IPO Year | N/A | 2019 |
| Metric | DUOT | CABA |
|---|---|---|
| Price | $10.99 | $2.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $14.00 | ★ $14.57 |
| AVG Volume (30 Days) | 193.6K | ★ 1.8M |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,026,308.00 | N/A |
| Revenue This Year | $292.26 | N/A |
| Revenue Next Year | $43.21 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 159.00 | N/A |
| 52 Week Low | $3.84 | $0.99 |
| 52 Week High | $12.17 | $3.67 |
| Indicator | DUOT | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 58.98 | 43.93 |
| Support Level | $9.25 | $2.12 |
| Resistance Level | $12.17 | $2.49 |
| Average True Range (ATR) | 0.67 | 0.12 |
| MACD | 0.16 | -0.02 |
| Stochastic Oscillator | 61.04 | 28.21 |
Duos Technologies Group Inc operating under its brand name duostech, designs, develops, deploys and operates intelligent technology solutions supporting rail, logistics and intermodal businesses that streamline operations, improve safety and reduce costs. The company's main offering, the Railcar Inspection Portal (RIP), provides both freight and transit railroad customers and select government agencies the ability to conduct fully automated railcar inspections of trains that are moving at full speed. It has also developed the Automated Logistics Information System (ALIS) which automates gatehouse operations where transport trucks enter and exit large logistics and intermodal facilities. Its segments are Rail, Commercial, Governments, Banking and AI.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.